Jahraus CD, Wallner PE, Heron DE, Crook W, Finkelstein SE, Harris AA, Kestin L, Landau E, Rivera D, Thomas TO, and Koontz BF
Radiation oncology is among the most data-driven specialties in medicine. Recently, a wealth of peer-reviewed data has been published supporting the treatment of oligometastatic malignancies, demonstrating improved survival with metastasis-directed therapy, such as stereotactic body radiation therapy (SBRT), when combined with appropriate patient selection and treatment. However, there are currently few, if any, established guidelines that synthesize the abundance of data specific to radiotherapy into a single, easily accessed resource for clinicians. ACROPath® is a major initiative of the American College of Radiation Oncology (ACRO) that aims to present aggregated clinical pathway data in a highly usable format that is readily accessible to clinicians at the point of care in real time. The oligometastases pathway is the first published algorithm in this collection, with additional pathways anticipated in future publications. Clinical radiation oncologists with expertise in the treatment and management of oligometastatic disease were recruited from across ACRO's diverse membership, including both academic and private practice physicians, to ensure a broad-based experience and insight. Individual participants were assigned subsections of the pathway for guideline development, and then, each subsection was presented to the full group for evaluation and consensus development based on published data. Rather than presenting an unstructured set of treatment options, as is common in other treatment guidelines, this initiative aimed to categorize appropriate treatments based on published clinical evidence in a hierarchy further ranked by efficacy, toxicity, and cost. Based on these strata, treatment recommendations were collated and grouped into three rank categories (gold, silver, or bronze) to denote the degree of applicability. The team assembled an interactive document that will eventually be available online, and it is summarized in detail here. Recommendations are grouped both by the anatomic site of metastasis and by the primary tumor type, recognizing that original histology might impact the treatment differently in different anatomic locations. After a review of available published clinical evidence, the committee reached a consensus on all recommendations presented, categorizing each option as gold, silver, or bronze to guide clinicians appropriately. This first iteration of ACROPath® Oligometastases represents one of the few comprehensive clinical decision support tools available for managing patients with limited metastatic disease. It presents available data in a highly accessible, easily used reference, which will be formally reviewed and updated by the committee as frequently as emerging data requires, likely at six- to 12-month intervals., Competing Interests: Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: Paul Wallner declare(s) personal fees from Nanocan Therapeutics. Medical advisory board. Tarita Thomas declare(s) personal fees from MJH Life Sciences. Paul Wallner, William Crook, and Evan Landau declare(s) employment from GenesisCare USA. Paul Wallner, former senior vice president for clinical affairs. Paul Wallner declare(s) employment from American Board of Radiology. Former associate executive director for radiation oncology. Christopher Jahraus declare(s) personal fees from Elekta. Site visit fees, consultant, advisory board member. Christopher Jahraus, Tarita Thomas, and Alexander Harris declare(s) non-financial support from American Medical Association. Served as ACRO delegate/advisor to RUC or CPT committees. Christopher Jahraus declare(s) personal fees from Blue Cross Blue Shield of Alabama. Former member of the preferred medical doctor advisory board. Bridget Koontz declare(s) non-financial support from Raythera Therapeutics, Inc. Board of directors. Bridget Koontz and Steven Finkelstein declare(s) personal fees from Blue Earth Diagnostics. Advisory board member. Steven Finkelstein declare(s) personal fees from Bayer. Consultant/speaker. Steven Finkelstein declare(s) personal fees from Johnson & Johnson. Consultant/speaker. Steven Finkelstein declare(s) personal fees from Novartis. Consultant/speaker. Christopher Jahraus declare(s) a patent from Salix Pharmaceuticals. Co-maker of a use patent on rifaximin. Steven Finkelstein declare(s) personal fees from Pfizer. Consultant/speaker. Steven Finkelstein declare(s) personal fees from Dendreon. Consultant/speaker. Bridget Koontz and Steven Finkelstein declare(s) personal fees from Lantheus. Advisory board member. Christopher Jahraus declare(s) personal fees from Radformation. Software access. Steven Finkelstein declare(s) personal fees from AstraZeneca. Consultant/speaker. Christopher Jahraus declare(s) personal fees from Fuse Oncology. Development collaboration. Christopher Jahraus declare(s) Expert witness in patent dispute. from Klarity Medical. Christopher Jahraus, Tarita Thomas, Dwight Heron, Paul Wallner, Bridget Koontz, and Steven Finkelstein declare(s) non-financial support from American College of Radiation Oncology. College leadership roles, including deputy editor of CURiE channel on Cureus platform (Jahraus). Intellectual property info: The American College of Radiation Oncology (ACRO) claims copyright (©) and trademark (™) 2024 over the name "ACROPath" and over all intellectual works and content described and presented as part of the ACROPath clinical pathways. All rights reserved by the American College of Radiation Oncology (ACRO). Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Jahraus et al.)